{"denoms":[{"counts":[{"groupId":"BG000","value":"47"}],"units":"Participants"}],"groups":[{"description":"Cetuximab beginning weekly dose 400 mg/m\\^2 intravenous (IV), and 250 mg/m\\^2 weeks 2-6; Weekly Carboplatin AUC 2 and Paclitaxel 135 mg/m\\^2 for 6 courses.","id":"BG000","title":"Cetuximab + Carboplatin/Paclitaxel"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"21","upperLimit":"78","value":"53"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEDIAN","title":"Age Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"14"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"33"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"47"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}